Kenyan Health Patient Information Leaflet
Therapeutic agent (verify pharmacological class)
Therapeutic use is agent- and indication-specific within the class (Therapeutic agent (verify pharmacological class)). Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC. Hypertension
Starting dose: 250mg BD or TID x 2/7 adjust until the desired effect is achieved. Max. 3g daily. Children 10mg/kg daily in 2-4 doses [max. 65mg/kg or 3g daily whichever is less]. To minimize sedation, start dosage increases in the evening. When methyldopa tablets are added to a thiazide, the dosage of thiazide need not be changed. When methyldopa is given with other antihypertensives apart from thiazides for initial therapy the dosage of methyldopa should not exceed 500mg daily. After withdrawal of methyldopa, hypertension returns after 48 hours.
Peripheral oedema; drug fever; mental depression; anxiety; nightmares; unusually vivid dreams; hepatic disorders; colitis; auto-immune haemolytic anaemia; reversible leukopaenia; reversible granulocytopenia; myocarditis; pancreatitis; systemic lupus erythematosus [SLE]-like syndrome; thrombocytopenia; drowsiness; dryness of mouth; headache; decreased sexual ability or interest in sex; diarrhoea; hyperprolactinemia; nausea or vomiting; orthostatic hypotension; paresthesias; sinus bradycardia; stuffy nose.
Store as labelled. Keep out of reach of children.